Andson Biotech Inc. filed a Form D with the Securities and Exchange Commission on 2025-10-22.
Andson Biotech Inc. filed a Form D notice of an exempt securities offering with the SEC on October 22, 2025. The filing reports $4.74M sold. Its industry group is Biotechnology. It names Mason Chilmonczyk (Executive Officer, Director), Andrei Fedorov (Director), Thomas O'Brien (Director) (SEC Form D, October 22, 2025).
Is this your company?
Sell to companies like Andson Biotech Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-10-22 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Andson Biotech Inc.
Free to see. No signup.
More on the people and the money behind Andson Biotech Inc., from the filings we hold.
Biotechnology raises filed within 90 days of this one, largest first.
Get an email when Andson Biotech Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Andson Biotech Inc. raises, hires or launches. No email unless you switch it on.
Watch Andson Biotech Inc. →Get the full cited report on Andson Biotech Inc.
What the filing shows about Andson Biotech Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Andson Biotech Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Andson Biotech Inc.'s address as 1705 Commerce Dr Nw, Suite 100, Atlanta, GA 30318.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Andson Biotech Inc. is a registered filer with the SEC (CIK 2017131) and has filed since 2024-03-26. 2 filings are on record, the latest on 2025-10-22.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Andson Biotech Inc.'s Form D of 2025-10-22 names Mason Chilmonczyk, Andrei Fedorov, Thomas O'Brien and 3 more as its officers, directors or promoters.
Its new offerings report $8.34M sold across 2 offerings, as its own filings state.
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 766 filings in Biotechnology, totalled by week.
Checked away from the filing. What is below does not come from the record on sec.gov.
Simplify your mass spec sample preparation with our next-generation platform.
The title and description the site itself served, answering 200. Not a cached copy and not the company's directory entry — what was live when we asked.
Mason Chilmonczyk is named as Executive Officer and Director on the Form D that Andson Biotech Inc. filed with the SEC on 22 October 2025, one of 6 people that filing names.
Andrei Fedorov is named as Director on the Form D that Andson Biotech Inc. filed with the SEC on 22 October 2025, one of 6 people that filing names.
Thomas O'Brien is named as Director on the Form D that Andson Biotech Inc. filed with the SEC on 22 October 2025, one of 6 people that filing names.
James Ross is named as Director on the Form D that Andson Biotech Inc. filed with the SEC on 22 October 2025, one of 6 people that filing names.
Jim Filippini is named as Executive Officer on the Form D that Andson Biotech Inc. filed with the SEC on 22 October 2025, one of 6 people that filing names.
Glenn Epstein is named as Director on the Form D that Andson Biotech Inc. filed with the SEC on 22 October 2025, one of 6 people that filing names.
6 people named on the filing — 2 holding an executive role and 4 as directors only.
Named as of the 2025-10-22 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Andson Biotech Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Andson Biotech Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Andson Biotech Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Andson Biotech Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Andson Biotech Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov, and from the company's own site, read directly on 2026-10-30 (andsonbiotech.com).
Each opens in a new tab, filled in for Andson Biotech Inc.. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises in Atlanta
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/andson-biotech-inc-form-d-25000001